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ABSTRACT
Known and novel pathogens continue to afﬂict the world’s population, and we deploy existing and new
vaccines – the best type of weapon we’ve got – against them. One consequence is that we are
accumulating steadily more experience of both the scientiﬁc and the ethical requirements of conducting
vaccine trials in people. Good science is itself an ethical requirement, as it is meaningless to apply ethical
principles to a scientiﬁcally ﬂawed product or plan. Bad science can only be bad ethics. And we have
learned that ethical principles are a necessity when we apply the beneﬁts of science to the improving of
human health.
Recent epidemics have provided opportunities to expand our understanding of this ﬁeld and of the
many components of it that we recognize toQ3 be necessary to the ethical assessment of vaccines.
Community involvement
10 We have moved a long way from trials in which an unsuspect-
ing population meekly submitted to experimentation by a
learned, if well-meaning, body of outsiders whom none of
them had ever met or would ever meet again.1,2 We now know
that the population to be studied is central to both the science
15 and the ethics of a trial. The recent horrifying epidemic of
Ebola virus disease (EVD) in West Africa has provided new
examples of the necessity and effectiveness of community
involvement in a vaccine trial.
The people of Sierra Leone recently emerged from a 10-year
20 civil war, following a sequence of slavery, colonial rule and then an
oppressive regime. All this may have accounted for their reluctance
to trust outsiders. A groupwishing to run a trial of a new Ebola can-
didate vaccine recognized, as investigators now do, the need to
engage ﬁrst with the population on the ground and to understand
25 its concerns.3 They formed a community liaison team, a participant
advisory group and a social science team, all consisting mostly of
local community members or staff. These teams met and discussed
regularly. They discovered that many ‘small community leaders’
felt that their authority was being undermined by decisions of the
30 ‘big’ leaders and teams, and that the process for selection of individ-
uals to participate in the trial was perceived to be unfair. The insur-
ance taken out for participants was seen by some as evidence that
deaths were to be expected. By understanding these and other
issues, the investigators and teams were able to talk through appre-
35 hensions. A public lottery system was invented for selection of
enrollees. The major joint achievement of this process was to
engender an atmosphere of trust that enabled the study to proceed
and the community to feel properly involved.3
In a multi-country trial of a Group A meningococcal conju-
40 gate vaccine,4 investigators found it useful to include local
journalists in the liaison team on the ground. They also learned
the importance of including husbands and male household
heads in preliminary discussions about the trial. They found it
useful to bring participants to the laboratory to observe how
45blood was separated and tested, to allay rumors that blood was
being sold overseas.
An aspect of ‘community involvement’ that is sometimes
neglected is consultation with the wider local community, in
particular those working in the health care system (to whom
50individuals enrolled or encountered in the vaccine trial may be
referred for routine management of illness), and those in aca-
demic or NGO circles who may already be working in the area
chosen for the trial.5 What research has already been done, or
is planned, in the study area? Local clinical or academic experi-
55ence may be invaluable to the new investigators, and anyway it
would be discourteous not to discuss the plans fully with them
or even involve them in the study. High levels of government
must equally be aware and approving of plans. These commu-
nications, like those of local community involvement, are
60implied by the ethical principle of Respect for Persons and
Communities.
Consent
‘Informed consent’ requires both effective information and un-
coerced agreement to participate. New insights into the consent
65process have been afforded by recent trials. Describing their
experiences in 4 West African sites of a 9-site study of a menin-
gococcal A vaccine, Idoko and others noted and tackled several
difﬁculties:4 it was not always easy to identify the local guard-
ian, especially for older children; some local languages were
70spoken but not written, so that paper information sheets and
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consent forms were problematic; some were suspicious of sign-
ing – “Is my word not good enough?”
Several groups have found that pictures, diagrams or objects
(syringe, small sample container, ﬁlter paper) can help with
75 conveying information during the pre-consent process. To
explain biologic concepts, analogies may be useful – e.g. liken-
ing antibodies to soldiers.6 An individual who has been enrolled
in a previous study can provide reassuring information to those
considering whether to sign up for a new study. In a study of a
80 trial, one-to-one discussion between a team member and a par-
ticipant proved to have the greatest success in improving the
understanding of informed consent.7 It can be valuable to
review informed consent at every follow-up visit during the
trial.6
85 Whatever methods are used, it is increasingly recognized
that trust between investigators and the community is a crucial
requirement for true consent.3 In a review of HIV vaccine trials
in South Africa, the authors write: ‘“mistrust” is as important a
barrier to involvement in trials as “misinformation”’.6
90 Consent has many site-speciﬁc components and sensitivi-
ties: there are differences not only between but within coun-
tries. The plans for giving information and obtaining consent
must be undertaken afresh for any site where a vaccine trial is
planned.
95 Ancillary care
Engagement with the community does not end when the trial
begins, but should continue during and after it. For many years
there have been extensive discussions about the obligations that
a research group has – or does not have – to provide trial par-
100 ticipants with health beneﬁts that are not related to the trial.
CIOMS Guideline 21 makes the slightly odd statement that
“sponsors are…not obliged to provide health care services
beyond what is necessary for the conduct of research, but it is
morally praiseworthy to do so.”8 The Helsinki Declaration,
105 even in its latest (seventh) revision9 makes no mention of this
issue. Common sense suggests that if a trial subject suffers an
emergency when in the vicinity of a trial team, everything pos-
sible should be done to help. Some trials provide non-emer-
gency services such as treatment of HIV infection or
110 hypertension, measures that can save enrollees a lot of time
and trouble and can contribute to trust and cordiality within
the study. But if health care provision outside of the trial itself
is attempted on too ambitious a scale it can have adverse conse-
quences: it may disrupt local healthcare services, that properly
115 belong to local government; it can generate an undue induce-
ment to individuals to enrol in the trial; it may commence a
clinical relationship that cannot eventually be sustained; and it
can divert funds or staff time from the task of completing the
trial competently.10,11 In impoverished areas most studies now
120 at least offer emergency care and provide transport to an
appropriate local health facility. Some studies make a point of
checking that a referred person has been received and properly
cared for.6
There is no single blueprint for the provision of ancillary
125 care, except that those planning a trial must give the subject
careful thought in advance, discuss it extensively with the local
Research Ethics Committee (REC) and with the community,
and incorporate speciﬁc plans in the trial protocol that is then
reviewed by the REC.
130Capacity building
All vaccine trials, especially those conducted in an impover-
ished area, are opportunities to enhance local capacity. Taking
part in the conduct of a trial, especially being involved at plan-
ning, review and writing stages, is itself valuable experience for
135scientists and other staff on the ground. Several large trials
have incorporated formal training sessions or enabled local
staff to study for higher degrees. In the RTS,S malaria vaccine
Phase III multi-site and multi-country study,12 each study site
was linked to a health facility, which was upgraded to permit
140accurate identiﬁcation of endpoints and adverse events, the
improvements all being available to the population as a whole
for routine healthcare provision. Improvements to facilities on
the ground are now a common component of vaccine and
other trials in areas with limited resources.
145Trial design
The Ebola epidemic provided new insights into study design,
where science and ethics may sometimes appear to conﬂict.
Dealing with so contagious and deadly a disease, WHO made
the unprecedented recommendation for the immediate deploy-
150ment of a novel vaccine on the sole basis of its safety and
immunogenicity in the small number of subjects in a Phase 1
study, and some animal tests. The aim was to give staff and
community the chance of early protection – sooner than the
many years normally needed for the full trialing and licensing
155of a vaccine. There was an immediate ethical difﬁculty: if speed
was the purpose, how could it be ethical to run a standard ran-
domized controlled trial (RCT) in which a control group,
equally at risk of the disease, would receive some irrelevant
alternative vaccine? Yet an RCT is undoubtedly the best tool
160for assessing a vaccine.
One solution was to use a ring vaccination design,13 similar
to that which was successfully used in the later stages of the
eradication of smallpox. Close contacts of each index patient
with Ebola virus disease, and contacts of those contacts, were
165enrolled and randomized to receive immediate or delayed vac-
cine, the delay being 3 weeks – the incubation period of 95% of
EBV cases. The Ebola epidemic was waning by this time, but
the method could be revisited, probably in conjunction with
traditional RCTs, should another outbreak occur.
170After the trial
Developments in continued community engagement after the
trial is over have lagged behind those for the pre-trial period.
Our increasing awareness of the community’s point of view
and its centrality for the trial have led to progress in this aspect
175of trials. It is well recognized that participants and their com-
munity deserve and appreciate feedback about the results of a
trial.14
More problematic is the question of whether a vaccine that
has shown efﬁcacy in a trial should then be given to others in
180the community. In the case of a multicentre trial of a
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meningococcal type A conjugate vaccine,15 in which the new
vaccine performed better than the existing product, WHO rec-
ommended that the new vaccine should be given immediately
at the end of the trial to those participants in the trial who had
185 not received it (and not to others in the community, who will
wait until the new vaccine has been licensed and enough is
available for appropriate deployment).
Do investigators adhere to protocols and ethical
guidelines?
190 Trials usually include a Monitor who visits the trial site and
assesses to what extent the protocol is adhered to and guide-
lines are followed. Few of these assessments lead to publica-
tions. In a study of several HIV vaccine trials in progress in
South Africa, Slack16 found a high degree of adherence to pro-
195 tocols and to ethical guidelines, and observed that in some
respects the researchers’ ‘practices exceeded current recom-
mendations’, particularly in the area of providing prompt and
assisted access to local healthcare services for enrollees needing
them. In part this commendable difference was due to the fact
200 that guidelines provided little advice about referral to health
facilities. More studies of what actually happens on the ground
in a variety of vaccine trials would be beneﬁcial to the contin-
ued improvement of this discipline. Guidelines are not rules,
and in the quoted study the important observation was made
205 that ‘protocol declarations are viewed as potentially locking
investigators into ethically approved strategies that might pre-
vent ﬂexible, innovative responses’.
The 4 ethical principles applied to vaccine trials
Respect (Autonomy), Beneﬁcence, Non-Maleﬁcence and Jus-
210 tice are all woven into the conduct of vaccine trials. Respect is
evident in communication with individuals and communities –
including those of local health services and academia – before,
during and after a trial, and in being aware of traditions, sensi-
tivities and concerns. Beneﬁcence implies that an efﬁcacious
215 product will beneﬁt trial participants, and that local health and
academic capacities will be strengthened. Non-maleﬁcence is
written into the protocol’s extensive schemes for detecting reac-
tions and adverse events, and must also pay attention to the
local health, academic and political context. Justice must ensure
220 that the hardships and beneﬁts of research are distributed with
fairness.
Vaccine trials in people share ethical requirements with
all forms of human scientiﬁc experimentation, but vaccines
are special in many ways. They target conditions that cause
225 or have caused enormous devastation to life and health,
they harness the body’s own mechanisms for defeating
pathogens, their delivery is among the simplest and briefest
known to health care, and their effect may be prolonged or
lifelong. By contrast, the measures required to provide alter-
230 native means of prevention or to take care of victims of the
same pathogens can be complex, continuing, cumbersome
and costly.
Of the 4 primary pillars of health ethics, one is therefore par-
ticularly crucial for the study of vaccines: Beneﬁcence. Vaccines
235 can be of such great beneﬁt that failing to put money and effort
into developing and testing them is unethical. This does not
mean that the other 3 principles do not apply. They do; and the
application of the last 3 principles is all the more important
because of the need urged on us by the ﬁrst – to get on with
240making and testing vaccines.
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